BHV3000-312

I'm Interested!

Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age

Sex at Birth: Any
Age: Child (Birth - 17)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase III
Conditions Being Studied: Migraine

Study Purpose

Biohaven Pharmaceuticals (Biohaven) is studying a drug called rimegepant as a possible treatment for migraine in children and adolescents. The main purpose of this study is to learn how well the study drug works and how safe the study drug is in children and young people compared with placebo.

Who Can Participate

Age: 6-18

Principal Investigator
Jennifer Waldron DO

Department/Division
Neurology (Pediatrics)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20211258 /SITE00001565
StudyID: 2021-0774
ClinicalTrials.gov: NCT04743141

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422